ANALYSIS OF THE MEDICINES’ RANGE FOR THERAPY OF PATIENTS WITH STABLE ANGINA IN THE RUSSIAN FEDERATION

Cardiovascular diseases are one of the leading mortality causes in the world as well as in Russia. According to the Federal State Statistics Service in Russian Federation for 2018, cardiovascular diseases are 46% in the structure of the deaths. Coronary artery disease is the most common cause in the mortality structure of people of working age.The Russian clinical guidelines for the treatment of stable coronary heart disease have proposed effective and safe groups of drugs, namely C07 «Beta blocking agents», C08 «Calcium channel blockers», C01DA «Organic nitrates» as well as a number of international nonproprietary names - ivabradinum, ranolazine, nicorandilum, molsidominum and trimethazidinum.The aim of the study is to analyze the medicines range for therapy of patients with stable angina in the Russian Federation.It’s shown that the largest (over 50%) share of drugs for the stable coronary artery disease pathogenetic therapy is represented by national manufacturers. At the same time, India brings the most (8-10%) contribution into the structure of import. Supply analysis demonstrates that the group C07 «Beta blocking agents» is represented by 20 INN for the basic therapy of stable angina, C08«Calcium channel blockers» - 33 INN, C01DA «Organic nitrates» - 5 INN. The calculated indexes of range latitude in each group(0,5 and less) allow to conclude that the variability of therapy is limited by the nomenclature of registered in Russia medicines for patients with the studied pathology.

стабильная ишемическая болезнь сердца, российский фармацевтический рынок, stable coronary artery disease, Russian pharmaceutical market